XTX Topco Ltd Sells 22,227 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

XTX Topco Ltd lessened its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 45.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,384 shares of the biopharmaceutical company’s stock after selling 22,227 shares during the quarter. XTX Topco Ltd’s holdings in Puma Biotechnology were worth $67,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Assenagon Asset Management S.A. grew its stake in Puma Biotechnology by 99.9% during the second quarter. Assenagon Asset Management S.A. now owns 140,205 shares of the biopharmaceutical company’s stock valued at $457,000 after acquiring an additional 70,060 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Puma Biotechnology by 63.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company’s stock valued at $1,007,000 after purchasing an additional 120,104 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of Puma Biotechnology during the 2nd quarter valued at $335,000. Rhumbline Advisers increased its holdings in shares of Puma Biotechnology by 2,309.9% in the second quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 48,184 shares during the period. Finally, Victory Capital Management Inc. purchased a new stake in shares of Puma Biotechnology in the second quarter worth $54,000. 61.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PBYI shares. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Wednesday, November 20th. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI opened at $2.75 on Friday. The company’s fifty day moving average price is $2.95 and its 200-day moving average price is $3.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The firm has a market capitalization of $134.99 million, a price-to-earnings ratio of 5.73 and a beta of 1.08. Puma Biotechnology, Inc. has a one year low of $2.22 and a one year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. During the same quarter last year, the business posted $0.12 earnings per share. On average, equities research analysts anticipate that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.